Skip to content
20-F

Annual Report (Foreign)

China SXT Pharmaceuticals, Inc. SXTC

0001213900-25-069688

← back to feed
Filed
Jul 31, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Mar 31, 2025 1.42M sh
Shares Diluted restated FY 2025 · Mar 31, 2024 108.43K sh
Shares Diluted restated FY 2025 · Mar 31, 2023 33.37K sh
Shares Outstanding FY 2025 · Mar 31, 2025 0 sh
Operating Cash Flow FY 2025 · Mar 31, 2025 −$2.35M
Operating Cash Flow FY 2025 · Mar 31, 2024 −$1.93M
Operating Cash Flow FY 2025 · Mar 31, 2023 −$80.76K
Long Term Debt FY 2025 · Mar 31, 2025 $96.26K
Long Term Debt FY 2025 · Mar 31, 2024 $117.13K
Short Term Debt FY 2025 · Mar 31, 2025 $702.18K
Short Term Debt FY 2025 · Mar 31, 2024 $493.05K
Cash And Equivalents FY 2025 · Mar 31, 2025 $18.1M
Cash And Equivalents FY 2025 · Mar 31, 2024 $12.07M
Stockholders Equity FY 2025 · Mar 31, 2025 $15.44M
Stockholders Equity FY 2025 · Mar 31, 2024 $13.93M
Stockholders Equity FY 2025 · Mar 31, 2023 $14.69M
Current Liabilities FY 2025 · Mar 31, 2025 $6.01M
Current Liabilities FY 2025 · Mar 31, 2024 $8.9M
Total Liabilities FY 2025 · Mar 31, 2025 $6.22M
Total Liabilities FY 2025 · Mar 31, 2024 $9.2M
Current Assets FY 2025 · Mar 31, 2025 $21.3M
Current Assets FY 2025 · Mar 31, 2024 $14.23M
Total Assets FY 2025 · Mar 31, 2025 $21.66M
Total Assets FY 2025 · Mar 31, 2024 $23.13M
Eps Diluted FY 2025 · Mar 31, 2025 −$2.32
Eps Diluted restated FY 2025 · Mar 31, 2024 −$28.58
Eps Diluted restated FY 2025 · Mar 31, 2023 −$177.84
Eps Basic FY 2025 · Mar 31, 2025 −$2.32
Eps Basic restated FY 2025 · Mar 31, 2024 −$28.58
Eps Basic restated FY 2025 · Mar 31, 2023 −$177.84
Sga Expense FY 2025 · Mar 31, 2025 $2.76M
Sga Expense FY 2025 · Mar 31, 2024 $2.64M
Sga Expense FY 2025 · Mar 31, 2023 $5.65M
Net Income FY 2025 · Mar 31, 2025 −$3.3M
Net Income FY 2025 · Mar 31, 2024 −$3.1M
Net Income FY 2025 · Mar 31, 2023 −$5.93M
Operating Income FY 2025 · Mar 31, 2025 −$2.68M
Operating Income FY 2025 · Mar 31, 2024 −$2.52M
Operating Income FY 2025 · Mar 31, 2023 −$5.61M
Gross Profit FY 2025 · Mar 31, 2025 $367.43K
Gross Profit FY 2025 · Mar 31, 2024 $553.97K
Gross Profit FY 2025 · Mar 31, 2023 $426.27K
Cost Of Revenue FY 2025 · Mar 31, 2025 $1.37M
Cost Of Revenue FY 2025 · Mar 31, 2024 $1.37M
Cost Of Revenue FY 2025 · Mar 31, 2023 $1.55M
Stock Issued FY 2025 · Feb 25, 2025 3 sh
Stock Issued restated FY 2025 · Oct 5, 2023 3 sh
Stock Issued FY 2025 · Sep 29, 2023 3 sh
Stock Issued restated FY 2025 · May 19, 2022 3 sh
Stock Issued restated FY 2025 · Feb 22, 2021 3 sh